Structure-activity relationship study of [1,2,3]thiadiazole necroptosis inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 24, 2007, Pages 6836-6840

  Teng, Xin ^a   Keys, Heather ^b   Jeevanandam, Arumugasamy ^c   Porco Jr , John A ^c   Degterev, Alexei ^b   Yuan, Junying ^d   Cuny, Gregory D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Boston University   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

1,2,3 Thiadiazole; Caspase independent; Cell death; Necroptosis; Necrosis

Indexed keywords

1,2,3 THIADIAZOLE DERIVATIVE; 2,6 DIHALOBENZYLAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; NECROPTOSIS INHIBITOR; NECROSTATIN DERIVATIVE; THIADIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BRAIN ISCHEMIA; CELL DEATH; CELL TYPE; CONTROLLED STUDY; DRUG POTENCY; ENANTIOMER; ENZYME MECHANISM; HUMAN; HUMAN CELL; LIGAND BINDING; LIVER INJURY; NECROPTOSIS; STRUCTURE ACTIVITY RELATION; TRAUMATIC BRAIN INJURY;

APOPTOSIS; HUMANS; JURKAT CELLS; MOLECULAR STRUCTURE; NECROSIS; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35848945069     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.10.024     Document Type: Article

References (35)

1. Wyllie A.H., Kerr J.F.R., and Currie A.R. Int. Rev. Cytol. 68 (1980) 251
2. Cryns V., and Yuan J. Genes Dev. 12 (1998) 1551
3. Yuan J., and Yankner B.A.. Nature 407 (2000) 802
4. Talanian R.V., Brady K.D., and Cryns V.L. J. Med. Chem. 43 (2000) 3351
5. Moore J.D., Rothwell N.J., and Gibson R.M. Br. J. Pharmacol. 135 (2002) 1069 and references therein
6. Boyce M., Degterev A., and Yuan J. Cell Death Differ. 11 (2004) 29
7. For literature related to caspase-independent cell death, see. Kitanaka C., and Kuchino Y. Cell Death Differ. 6 (1999) 508
8. Fiers W., Beyaert R., Declercq W., and Vandenabeele P. Oncogene 18 (1999) 7719
9. Borner C., and Monney L. Cell. Death Differ. 6 (1999) 497
10. Edinger A.L., and Thompson C.B. Curr. Opin. Cell Biol. 16 (2004) 663
11. Yu L., Alva A., Su H., Dutt P., Freundt E., Welsh S., Baehrecke E.H., and Lenardo M.J. Science 304 (2004) 1500
12. Chipuk J.E., and Green D.R. Nat. Rev. Mol. Cell Biol. 6 (2005) 268
13. Bröker L.E., Kruyt F.A.E., and Giaccone G. Clin. Cancer Res. 11 (2005) 3155
14. Fink S.L., and Cookson B.T. Infect. Immun. 73 (2005) 1907
15. Kroemer G., and Martin S.J. Nat. Med. 11 (2005) 725
16. Vandenabeele P., Vanden Berghe T., and Festjens N. Sci. STKE 358 (2006) pe44
17. Martinet W., Schrijvers D.M., Herman A.G., and De Meyer G.R. Autophagy 2 (2006) 312
18. Degterev A., Huang Z., Boyce M., Li Y., Jagtap P., Mizushima N., Cuny G.D., Mitchison T., Moskowitz M., and Yuan J. Nat. Chem. Biol. 1 (2005) 112
19. Martin L.J., Al-Abdulla N.A., Brambrink A.M., Kirsch J.R., Sieber F.E., and Portera-Cailliau C. Brain Res. Bull. 46 (1998) 281
20. Lo E.H., Dalkara T., and Moskowitz M.A. Nat. Rev. Neurosci. 4 (2003) 399
21. McCully J.D., Wakiyama H., Hsieh Y.J., Jones M., and Levitsky S. Am. J. Physiol. Heart Circ. Physiol. 286 (2004) H1923
22. Yuan J., Lipinski M., and Degterev A. Neuron 40 (2003) 401
23. Teng X., Degterev A., Jagtap P., Xing X., Choi S., Denu R., Yuan J., and Cuny G.D. Bioorg. Med. Chem. Lett. 15 (2005) 5039
24. Jagtap P.G., Degterev A., Choi S., Keys H., Yuan J., and Cuny G.D. J. Med. Chem. 50 (2007) 1886
25. Wang K., Li J., Degterev A., Hsu E., Yuan J., and Yuan C. Bioorg. Med. Chem. Lett. 17 (2007) 1455
26. Several other biological activities of 4-alkyl-[1,2,3]thiadiazole-5-benzylamides have been reported, including inhibition of I-kappa B kinase complex (IKK), see: Pitts, W. J.; Kempson, J.; Guo, J.; Das, J.; Langevine, C. M.; Spergel, S. H.; Watterson, S. H. WO 2006122137, 2006 and as agents to control plant diseases.
27. See: Umetani, K; Shimaoka, T.; Yamaguchi, M.; Oda, M.; Kyomura, N.; Takemoto, T.; Kikutake, K. WO 2006098128, 2006.
28. Oikawa Y., Sugano K., and Yonemitsu O. J. Org. Chem. 43 (1978) 2087
29. Thomas E.W., Nishizawa E.E., Zimmermann D.C., and Williams D.J. J. Med. Chem. 28 (1985) 442
30. Polniaszek R.P., Belmont S.E., and Alvarez R. J. Org. Chem. 55 (1990) 215
31. Itsuno S., Hachisuka C., and Ito K. J. Chem. Soc., Perkin Trans. 1 (1991) 1767
32. Lebel H., and Leogane O. Org. Lett. 7 (2005) 4107
33. Burk M.J., Wang Y.M., and Lee J.R. J. Am. Chem. Soc. 118 (1996) 5142
34. 50 values were calculated using nonlinear regression analysis of sigmoid dose-response (variable slope) curves from plots of log[I] verses viability values.
35. Compound 52 was prepared in low yield (10%) by allowing 16 to react with 2,6-difluoroaniline in THF and pyridine at room temperature. The reaction with 2-chloro-6-fluoroaniline was unsuccessful presumably due to increased steric hindrance.